Background
swapnil hiremath
Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

Healing, Hype, or Harm: The NefIgArd trial
Background
Cristina Adriana Popa
PRAECISely Predicting Preeclampsia

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

PRAECISely Predicting Preeclampsia
Background
swapnil hiremath
The Worldwide Shadow of Kidney Disease

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

The Worldwide Shadow of Kidney Disease
Background
swapnil hiremath
The PROTECT-V platform - RENALISM no more?

This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.

The PROTECT-V platform - RENALISM no more?
Background
swapnil hiremath
Dialysis dreams and sleepless realities: the ...

This week, we will discuss the SLEEP-HD trial, which examined if trazodone or CBT are better than placebo in helping people sleep.

Dialysis dreams and sleepless realities: the SLEEP-HD trial

ELAIN-AKI

The AKIKI & ELAIN AKI #NephJC wrap up

The AKI timing chats were very ....fast-paced? Lot of great input from the authors, Stephane Gaudry (who made it to both chats) and John Kellum. We had over 80 participants in all

And for those who missed it, check out the great curations via our exemplary storifier, Hector: